Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) and is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate (a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome.

Cat. No.	Product name	CAS No.	Purity
T12128	Mutant IDH1-IN-2	1429176-69-1	98%
T12128	Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor
T7741	DS-1001b	1898207-64-1	100%
T7741	DS-1001b is an inhibitor of mutant IDH-1 (Isocitrate Dehydrogenase-1)
T16161	Mutant IDH1 inhibitor	1429180-08-4	97.72%
T16161	Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
T7307	Vorasidenib	1644545-52-7	98%
T7307	Vorasidenib is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively)
T1809	AGI-6780	1432660-47-3	98.19%
T1809	AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant.
T2043	Mutant IDH1-IN-1	1355326-21-4	98.98%
T2043	Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM.
T2104	AGI-5198	1355326-35-0	99.23%
T2104	AGI-5198 is a highly effective and specific inhibitor of IDH1 R132H/R132C mutants (IC50: 0.07/0.16 μM).
T2346	Enasidenib	1446502-11-9	99.45%
T2346	Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineopl...
T16384	Olutasidenib	1887014-12-1	99.59%
T16384	Olutasidenib is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain pen...
TQ0042	BAY-1436032	1803274-65-8	99.65%
TQ0042	BAY-1436032 is a novel, selective and orally available inhibitor of pan-mutant isocitrate dehydrogenase 1 (IDH1).
T3617	Ivosidenib	1448347-49-6	99.7%
T3617	Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a...